The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Open accessAbstract
The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK inhibitors (BTKis) in the clinic has increased considerably and currently amounts to at least 22. First-in-class was ibrutinib, an irreversible binder forming a covalent bond to a cysteine in the catalytic region of the kinase, for which we have identified 228 active trials listed at ClinicalTrials.gov. Next-generation inhibitors, acalabrutinib and zanubrutinib, are approved both in the United States and in Europe, and zanubrutinib also in China, while tirabrutinib is currently only registered in Japan. In most cases, these compounds have been used for the treatment of B-lymphocyte tumors. However, an increasing number of trials instead addresses autoimmunity and inflammation in multiple sclerosis, rheumatoid arthritis, pemphigus and systemic lupus erythematosus with the use of either irreversibly binding inhibitors, e.g., evobrutinib and tolebrutinib, or reversibly binding inhibitors, like fenebrutinib. Adverse effects (AEs) have predominantly implicated inhibition of other kinases with a BTKi-binding cysteine in their catalytic domain. Analysis of the reported AEs suggests that ibrutinib-associated atrial fibrillation is caused by binding to ERBB2/HER2 and ERBB4/HER4. However, the binding pattern of BTKis to various additional kinases does not correlate with the common assumption that skin manifestations and diarrhoeas are off-target effects related to EGF receptor inhibition. Moreover, dermatological toxicities, diarrhoea, bleedings and invasive fungal infections often develop early after BTKi treatment initiation and subsequently subside. Conversely, cardiovascular AEs, like hypertension and various forms of heart disease, often persist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
BRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492
Vetrie, D., Vořechovský, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarström, L., Kinnon, C., Levinsky, R., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,461
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“The commonest cause of resistance is the C481 to serine substitution in BTK (Woyach et al., 2014, 2017; Hamasy et al., 2017; Quinquenel et al., 2019).”
BackgroundAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Ibrutinib (Imbruvica R (cid:13) ), the first-in-class BTK inhibitor (BTKi), is an irreversible binder, which has revolutionized the therapeutic landscape for B-cell malignancies (Honigberg et al., 2010; Advani et al., 2013).”
BackgroundIbrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726 · cited 1×
“…receptor (BCR) signaling pathway led to the deciphering of the central role of Bruton’s tyrosine kinase (BTK) and the importance of its inhibition as an effective strategy for the treatment of B-cell malignancies (Herman et al., 2011; Smith, 2017; Pal Singh et al., 2018; Lucas and Woyach, 2019).”
BackgroundByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 554
BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2282 · Cited by 484
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25638 · Cited by 473
Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0602-x · Cited by 467
Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Mato, A. R., Nabhan, C., Thompson, M. C., Lamanna, N., Brander, D. M., Hill, B., Howlett, C., Skarbnik, A., Cheson, B. D., Zent, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182907 · Cited by 456
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 403
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C.-H., Mok, T. S., & Loong, H. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 388
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Farooqui, M. Z. H., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., Herman, S. E. M., Tian, X., Marti, G., Soto, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71182-9 · Cited by 372
Ghia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., de la Serna, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03355 · Cited by 372
Tam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., et al. (2019) · Blood · doi:10.1182/blood.2019001160 · Cited by 361
Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00687 · Cited by 359
O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Österborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30212-1 · Cited by 340
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Jain, P., Keating, M., Wierda, W., Estrov, Z., Ferrajoli, A., Jain, N., George, B., James, D., Kantarjian, H., Burger, J., et al. (2015) · Blood · doi:10.1182/blood-2014-09-603670 · Cited by 334
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Levade, M., David, E., Garcia, C., Laurent, P.-A., Cadot, S., Michallet, A.-S., Bordet, J.-C., Tam, C., Sié, P., Ysebaert, L., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583294 · Cited by 321
Smith, C. I. E., Islam, T. C., Mattsson, P. T., Mohamed, A. J., Nore, B. F., & Vihinen, M. (2001) · BioEssays · doi:10.1002/bies.1062 · Cited by 313
Self-citationEarly-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Ghez, D., Calleja, A., Protin, C., Baron, M., Ledoux, M.-P., Damaj, G., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., et al. (2018) · Blood · doi:10.1182/blood-2017-11-818286 · Cited by 307
Smith, C. I. E., Baskin, B., Humire-Greiff, P., Zhou, J. N., Olsson, P. G., Maniar, H. S., Kjellén, P., Lambris, J. D., Christensson, B., Hammarström, L., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.557 · Cited by 305
Self-citationIbrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13651 · Cited by 279
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy175 · Cited by 271
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
X-Linked Agammaglobulinemia A Clinical and Molecular Analysis
Ochs, H. D., & Edvard Smith, C. I. (1996) · Medicine · doi:10.1097/00005792-199611000-00001 · Cited by 266
Cardiovascular Toxicities Associated With Ibrutinib
Salem, J.-E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.056 · Cited by 266
Hypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., et al. (2019) · Blood · doi:10.1182/blood.2019000840 · Cited by 260
Crawford, J. J., Johnson, A. R., Misner, D. L., Belmont, L. D., Castanedo, G., Choy, R., Coraggio, M., Dong, L., Eigenbrot, C., Erickson, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01712 · Cited by 257
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu, J., Zhang, M., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0250-9 · Cited by 254
A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen
Quek, L. S., Bolen, J., & Watson, S. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70471-3 · Cited by 253
Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J.-P., Ho, P. Y., McKenna, K. M., Cheshier, S., Zhang, M., Guo, N., Gip, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424907112 · Cited by 253
Liu, X., Liang, Y., Song, R., Yang, G., Han, J., Lan, Y., Pan, S., Zhu, M., Liu, Y., Wang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0838-5 · Cited by 252
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
Kamel, S., Horton, L., Ysebaert, L., Levade, M., Burbury, K., Tan, S., Cole-Sinclair, M., Reynolds, J., Filshie, R., Schischka, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.247 · Cited by 231
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
Small Molecule NF-κB Pathway Inhibitors in Clinic
Ramadass, V., Vaiyapuri, T., & Tergaonkar, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145164 · Cited by 210
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Ibrutinib-Associated Atrial Fibrillation
Ganatra, S., Sharma, A., Shah, S., Chaudhry, G. M., Martin, D. T., Neilan, T. G., Mahmood, S. S., Barac, A., Groarke, J. D., Hayek, S. S., et al. (2018) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2018.06.004 · Cited by 205
de Weers, M., Verschuren, M. C. M., Kraakman, M. E. M., Mensink, R. G. J., Schuurman, R. K. B., van Dongen, J. J. M., & Hendriks, R. W. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231210 · Cited by 202
Survival of leukemic B cells promoted by engagement of the antigen receptor
Bernal, A., Pastore, R. D., Asgary, Z., Keller, S. A., Cesarman, E., Liou, H.-C., & Schattner, E. J. (2001) · Blood · doi:10.1182/blood.v98.10.3050 · Cited by 195
Awan, F. T., Schuh, A., Brown, J. R., Furman, R. R., Pagel, J. M., Hillmen, P., Stephens, D. M., Woyach, J., Bibikova, E., Charuworn, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030007 · Cited by 185
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J. P., Wierda, W., Zhao, W., Heerema, N. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2856 · Cited by 185
Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3703 · Cited by 184
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
Treon, S. P., Gustine, J., Meid, K., Yang, G., Xu, L., Liu, X., Demos, M., Kofides, A., Tsakmaklis, N., Chen, J. G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.6426 · Cited by 182
Byrd, J. C., Wierda, W. G., Schuh, A., Devereux, S., Chaves, J. M., Brown, J. R., Hillmen, P., Martin, P., Awan, F. T., Stephens, D. M., et al. (2020) · Blood · doi:10.1182/blood.2018884940 · Cited by 178
Herbst, S., Shah, A., Mazon Moya, M., Marzola, V., Jensen, B., Reed, A., Birrell, M. A., Saijo, S., Mostowy, S., Shaunak, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404556 · Cited by 176
Lipsky, A. H., Farooqui, M. Z. H., Tian, X., Martyr, S., Cullinane, A. M., Nghiem, K., Sun, C., Valdez, J., Niemann, C. U., Herman, S. E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.126672 · Cited by 172
Angst, D., Gessier, F., Janser, P., Vulpetti, A., Wälchli, R., Beerli, C., Littlewood-Evans, A., Dawson, J., Nuesslein-Hildesheim, B., Wieczorek, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01916 · Cited by 172
Owen, R. G., McCarthy, H., Rule, S., D'Sa, S., Thomas, S. K., Tournilhac, O., Forconi, F., Kersten, M. J., Zinzani, P. L., Iyengar, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30210-8 · Cited by 167
Ahn, I. E., Jerussi, T., Farooqui, M., Tian, X., Wiestner, A., & Gea-Banacloche, J. (2016) · Blood · doi:10.1182/blood-2016-06-722991 · Cited by 165
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1409 · Cited by 165
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Stephens, D. M., & Byrd, J. C. (2019) · Blood · doi:10.1182/blood-2018-11-846808 · Cited by 160
Treon, S. P., Meid, K., Gustine, J. N., Yang, G., Xu, L., Liu, X., Patterson, C. J., Hunter, Z. R., Branagan, A. R., Laubach, J. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00555 · Cited by 160
Liu, H., Wu, Y., Lv, T., Yao, Y.-W., Xiao, Y., Yuan, D., & Song, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055128 · Cited by 156
Caldwell, R. D., Qiu, H., Askew, B. C., Bender, A. T., Brügger, N., Camps, M., Dhanabal, M., Dutt, V., Eichhorn, T., Gardberg, A. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00794 · Cited by 152
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P., & van Gelder, M. (2017) · Haematologica · doi:10.3324/haematol.2017.164103 · Cited by 147
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
Basile, D., Nardo, P. D., Corvaja, C., Garattini, S. K., Pelizzari, G., Lisanti, C., Bortot, L., Ros, L. D., Bartoletti, M., Borghi, M., et al. (2019) · Cancers · doi:10.3390/cancers11060857 · Cited by 146
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
Haselmayer, P., Camps, M., Liu‐Bujalski, L., Nguyen, N. T. K., Morandi, F., Head, J. C., O’Mahony, A., Zimmerli, S. C., Bruns, L., Bender, A. T., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800583 · Cited by 143
Targets for Ibrutinib Beyond B Cell Malignancies
Berglöf, A., Hamasy, A., Meinke, S., Palma, M., Krstic, A., Månsson, R., Kimby, E. K., Österborg, A., & Smith, C. I. E. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12333 · Cited by 138
Self-citationTillman, B. F., Pauff, J. M., Satyanarayana, G., Talbott, M., & Warner, J. L. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13020 · Cited by 138
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137
Cohen, S. B., Tuckwell, K., Katsumoto, T. R., Zhao, R. Z., Galanter, J., Lee, C., Rae, J., Tóth, B. I., Ramamoorthi, N., Hackney, J. A., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41275 · Cited by 135
Quinquenel, A., Fornecker, L.-M., Letestu, R., Ysebaert, L., Fleury, C., Lazarian, G., Dilhuydy, M.-S., Nollet, D., Guieze, R., Feugier, P., et al. (2019) · Blood · doi:10.1182/blood.2019000854 · Cited by 133
Skin problems and EGFR-tyrosine kinase inhibitor
Kozuki, T. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv207 · Cited by 129
Xu, W., Yang, S., Zhou, K., Pan, L., Li, Z., Zhou, J., Gao, S., Zhou, D., Hu, J., Feng, R., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00884-4 · Cited by 129
Targeting BTK in CLL: Beyond Ibrutinib
Bond, D. A., & Woyach, J. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00512-0 · Cited by 128
Bercusson, A., Colley, T., Shah, A., Warris, A., & Armstrong-James, D. P. H. (2018) · Blood · doi:10.1182/blood-2017-12-823393 · Cited by 126
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Sibaud, V., Beylot-Barry, M., Protin, C. A., Vigarios, É., Récher, C., & Ysebaert, L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00535-x · Cited by 124
Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib
Jain, P., Thompson, P. A., Keating, M. J., Estrov, Z. E., Ferrajoli, A., Jain, N., Kantarjian, H. M., Burger, J. A., O'Brien, S. M., & Wierda, W. G. (2017) · Cancer · doi:10.1002/cncr.30596 · Cited by 122
Watterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120
Waller, E. K., Miklos, D. B., Cutler, C. S., Arora, M., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Chang, S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.023 · Cited by 119
How I treat CLL patients with ibrutinib
Brown, J. R. (2017) · Blood · doi:10.1182/blood-2017-08-764712 · Cited by 116
Kiyohara, Y., Yamazaki, N., & Kishi, A. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.02.025 · Cited by 115
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Trotman, J., Opat, S., Gottlieb, D. J., Simpson, D., Marlton, P. V., Cull, G., Munoz, J. L., Tedeschi, A., Roberts, A. W., Seymour, J. F., et al. (2020) · Blood · doi:10.1182/blood.2020006449 · Cited by 115
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01318-8 · Cited by 113
Tam, C. S. L., Robak, T., Ghia, P., Kahl, B. S., Walker, P., Janowski, W., Simpson, D., Shadman, M. S., Ganly, P. S., Laurenti, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.259432 · Cited by 111
Interleukin-2-Inducible T-Cell Kinase (ITK) Deficiency - Clinical and Molecular Aspects
Ghosh, S., Bienemann, K., Boztuǧ, K., & Borkhardt, A. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0110-8 · Cited by 108
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Fiorcari, S., Maffei, R., Audrito, V., Martinelli, S., ten Hacken, E., Zucchini, P., Grisendi, G., Potenza, L., Luppi, M., Burger, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11782 · Cited by 108
Sun, C., Nierman, P., Kendall, E. K., Cheung, J., Gulrajani, M., Herman, S. E. M., Pleyer, C., Ahn, I. E., Stetler-Stevenson, M., Yuan, C. M., et al. (2020) · Blood · doi:10.1182/blood.2019003715 · Cited by 103 · cited 2×
“…TEC, since this AE has also been found after treatment with more selective BTKis, such as acalabrutinib and zanubrutinib (Byrd et al., 2020b; Ghia et al., 2020; Owen et al., 2020; Sharman et al., 2020; Song et al., 2020; Sun et al., 2020; Tam et al., 2020a; Trotman et al., 2020; Xu et al., 2020).”
BackgroundLiclican, A. C., Serafini, L., Xing, W., Czerwieniec, G. A., Steiner, B. H., Wang, T., Brendza, K. M., Lutz, J. D., Keegan, K. S., Ray, A. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129531 · Cited by 101
Haegebarth, A., Bie, W., Yang, R., Crawford, S. E., Vasioukhin, V. I., Fuchs, E. V., & Tyner, A. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01901-05 · Cited by 97
Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology
Chu, G. K. T., Versteeg, H. H., Verschoor, A. J., Trines, S. A. I. P., Hemels, M. E. W., Ay, C., Huisman, M. V., & Klok, F. A. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.03.005 · Cited by 97
Oda, A., Ikeda, Y., Ochs, H. D., Druker, B. J., Ozaki, K., Handa, M., Ariga, T., Sakiyama, Y., Witte, O. N., & Wahl, M. I. (2000) · PubMed · doi:10.1182/blood.v95.5.1663.005k44_1663_1670 · Cited by 93
Brown, J. R., Moslehi, J. J., Ewer, M. S., O'Brien, S. M., Ghia, P., Cymbalista, F., Shanafelt, T. D., Fraser, G. A. M., Rule, S. A., Coutre, S. E., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15690 · Cited by 93
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Rogers, K. A., Mousa, L., Zhao, Q., Bhat, S. A., Byrd, J. C., Boghdadly, Z. E., Guerrero, T., Levine, L. B., Lucas, F. M., Shindiapina, P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0481-1 · Cited by 90
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Sekiguchi, N., Rai, S., Munakata, W., Suzuki, K., Handa, H., Shibayama, H., Endo, T., Terui, Y., Iwaki, N., Fukuhara, N., et al. (2020) · Cancer Science · doi:10.1111/cas.14561 · Cited by 84
Hillmen, P., Brown, J. R., Eichhorst, B. F., Lamanna, N., O'Brien, S. M., Qiu, L., Salmi, T., Hilger, J. D., Wu, K., Cohen, A. C., et al. (2020) · Future Oncology · doi:10.2217/fon-2019-0844 · Cited by 83
Nicolson, P. L. R., Hughes, C. E., Watson, S., Nock, S. H., Hardy, A. T., Watson, C. N., Montague, S. J., Clifford, H., Huissoon, A. P., Malcor, J.-D. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193391 · Cited by 81
High incidence of atrial fibrillation in patients treated with ibrutinib
Baptiste, F., Cautela, J., Ancedy, Y., Resseguier, N., Aurran, T., Farnault, L., Escudier, M., Ammar, C., Gaubert, M., Dolladille, C., et al. (2019) · Open Heart · doi:10.1136/openhrt-2019-001049 · Cited by 77
Human Platelets Attenuate Aspergillus Species via Granule‐Dependent Mechanisms
Perkhofer, S., Kehrel, B. E., Dierich, M. P., Donnelly, J. P., Nußbaumer, W., Hofmann, J., von Eiff, C., & Lass‐Flörl, C. (2008) · The Journal of Infectious Diseases · doi:10.1086/591458 · Cited by 70
Gribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.15080 · Cited by 70
Reiff, S. D., Muhowski, E. M., Guinn, D., Lehman, A., Fabian, C. A., Cheney, C. M., Mantel, R., Smith, L., Johnson, A. J., Young, W. B., et al. (2018) · Blood · doi:10.1182/blood-2017-10-809020 · Cited by 69
Risk of Major Bleeding with Ibrutinib
Mock, J., Kunk, P. R., Palkimas, S., Sen, J. M., Devitt, M. E., Horton, B. J., Portell, C. A., Williams, M. E., & Maitland, H. S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.287 · Cited by 68
Brandhuber, B. J., Gómez, E. B., Smith, S. G., Eary, T., Spencer, S., Rothenberg, S. M., & Andrews, S. W. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.081 · Cited by 64
From identification of the BTK kinase to effective management of leukemia
Smith, C. I. E. (2016) · Oncogene · doi:10.1038/onc.2016.343 · Cited by 63
Self-citationWinqvist, M., Andersson, P., Asklid, A., Karlsson, K., Karlsson, C., Lauri, B., Lundin, J., Mattsson, M., Norin, S., Sandstedt, A. B., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198820 · Cited by 63
Hamasy, A., Wang, Q., Blomberg, K. E. M., Mohammad, D. K., Yu, L., Vihinen, M., Berglöf, A., & Smith, C. I. E. (2017) · Leukemia · doi:10.1038/leu.2016.153 · Cited by 62
Self-citationIbrutinib‐associated rash: a single‐centre experience of clinicopathological features and management
Iberri, D. J., Kwong, B. Y., Stevens, L. A., Coutre, S. E., Kim, J., Sabile, J. M. G., & Advani, R. H. (2016) · British Journal of Haematology · doi:10.1111/bjh.14302 · Cited by 62
Dobie, G., Kuriri, F. A., Omar, M. M. A., Alanazi, F. G., Gazwani, A. M., Tang, C. P. S., Sze, D., Handunnetti, S. M., Tam, C. S. L., & Jackson, D. E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000640 · Cited by 61
Gillooly, K. M., Pulicicchio, C. M., Pattoli, M. A., Cheng, L., Skala, S., Heimrich, E., McIntyre, K. W., Taylor, T. L., Kukral, D. W., Dudhgaonkar, S. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181782 · Cited by 59
A Specific Role of Phosphatidylinositol 3–Kinase γ
Bony, C., Roche, S., Shuichi, U., Sasaki, T., Crackower, M. A., Penninger, J. M., Mano, H., & Pucéat, M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.4.717 · Cited by 57
Messina, J. A., Maziarz, E. K., Spec, A., Kontoyiannis, D. P., & Perfect, J. R. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw261 · Cited by 57
Fiorcari, S., Maffei, R., Vallerini, D., Scarfò, L., Barozzi, P., Maccaferri, M., Potenza, L., Ghia, P., Luppi, M., & Marasca, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02158 · Cited by 57
Archibald, W. J., Rabe, K. G., Kabat, B., Herrmann, J., Ding, W., Kay, N. E., Kenderian, S. S., Muchtar, E., Leis, J. F., Wang, Y., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04094-3 · Cited by 55
Walter, H. S., Jayne, S., Rule, S. A., Cartron, G., Morschhauser, F., Macip, S., Karlin, L., Jones, C. H., Herbaux, C., Quittet, P., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765115 · Cited by 53
Btk inhibition treats TLR7/IFN driven murine lupus
Bender, A. T., Pereira, A., Fu, K., Samy, E. T., Wu, Y., Liu‐Bujalski, L., Caldwell, R. D., Chen, Y.-Y., Tian, H., Morandi, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.01.012 · Cited by 52
Munakata, W., Ando, K., Hatake, K., Fukuhara, N., Kinoshita, T., Fukuhara, S., Shirasugi, Y., Yokoyama, M., Ichikawa, S., Ohmachi, K., et al. (2019) · Cancer Science · doi:10.1111/cas.13983 · Cited by 51
Albini, A., Cesana, E., Donatelli, F., Cammarota, R., Bucci, E., Baravelli, M., Anza', C., & Noonan, D. (2011) · Future Cardiology · doi:10.2217/fca.11.54 · Cited by 47
Singer, S. B., Tan, S., Dewan, A. K., Davids, M. S., LaCasce, A. S., Treon, S. P., & LeBoeuf, N. R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.031 · Cited by 45
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 41
Targeting the epidermal growth factor receptor in solid tumors: focus on safety
Lucchini, E., Pilotto, S., Spada, E. L., Melisi, D., Bria, E., & Tortora, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.904283 · Cited by 40
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Busygina, K., Denzinger, V., Bernlochner, I., Weber, C., Lorenz, R. L., & Siess, W. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1687877 · Cited by 39
Goess, C., Harris, C. M., Murdock, S., McCarthy, R. W., Sampson, E. R., Twomey, R., Mathieu, S., Mario, R., Perham, M., Goedken, E. R., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1484269 · Cited by 38
Deletion of the Endothelial Bmx Tyrosine Kinase Decreases Tumor Angiogenesis and Growth
Holopainen, T., Alpuche, V. L., Zheng, W., Heljäsvaara, R., Jones, D., He, Y., Tvorogov, D., D’Amico, G., Wiener, Z., Andersson, L. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1070 · Cited by 35
Tuomi, J. M., Xenocostas, A., & Jones, D. L. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.001 · Cited by 33
Huang, S., Pan, J., Jin, J., Li, C.-Y., Li, X., Huang, J., Huang, X., Xiao, Y., Li, F., Yu, M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.008 · Cited by 29
Rule, S. A., Cartron, G., Fegan, C., Morschhauser, F., Han, L., Mitra, S. S., Salles, G. A., & Dyer, M. J. S. (2019) · Leukemia · doi:10.1038/s41375-019-0658-7 · Cited by 24
Estupiñan, H. Y., Bouderlique, T., He, C., Berglöf, A., Gupta, D., Saher, O., Cruz, M. Á. D., Peña‐Pérez, L., Yu, L., Zain, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001319 · Cited by 24
Self-citationPrecursor B-cell development in bone marrow of Good syndrome patients
Molina, L. D. P., Wentink, M. W. J., van Deuren, M., van Hagen, P. M., Smith, C. I. E., & van der Burg, M. (2019) · Clinical Immunology · doi:10.1016/j.clim.2018.11.009 · Cited by 21
Self-citationDistinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling
de Bruijn, M. J. W., Rip, J., van der Ploeg, E. K., van Greuningen, L. W., Ta, V. T. B., Kil, L. P., Langerak, A. W., Rimmelzwaan, G. F., Ellmeier, W., Hendriks, R. W., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601285 · Cited by 20
X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii
Jongco, A. M., Gough, J. D., Sarnataro, K., Rosenthal, D. W., Moreau, J., Ponda, P., & Bonagura, V. R. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.10.008 · Cited by 18
Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18
Cheng, M. P., Kusztos, A. E., Gustine, J. N., Dryden‐Peterson, S., Dubeau, T. E., Woolley, A. E., Hammond, S. P., Baden, L. R., Treon, S. P., Castillo, J. J., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15627 · Cited by 14
LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
Naeem, A. S., Nguy, W. I., Tyekucheva, S., Fernandes, S. M., Rai, V., Ebata, K. T., Gómez, E. B., Brandhuber, B. J., Rothenberg, S. M., & Brown, J. R. (2019) · Blood · doi:10.1182/blood-2019-124362 · Cited by 13
Stress signaling by Tec tyrosine kinase in the ischemic myocardium
Zhang, M. J., Franklin, S., Li, Y., Wang, S., Ru, X., Mitchell-Jordan, S. A., Mano, H., Stefani, E., Ping, P., & Vondriska, T. M. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00273.2010 · Cited by 12
Erbb2 Is Required for Cardiac Atrial Electrical Activity during Development
Tenin, G., Clowes, C., Wolton, K., Krejčí, E., WRIGHT, J. A., Lovell, S. C., Sedmera, D., & Hentges, K. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107041 · Cited by 11
Zhang, X., Ran, Y.-G., & Wang, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0180 · Cited by 11
Goodstal, S. M., Lin, J., Crandall, T., Crowley, L., Bender, A. T., Pereira, A., Soloviev, M., Wesolowski, J. S., Iadevaia, R., Schelhorn, S.-E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47735-z · Cited by 11
In vitro Coagulation Triggers Anti- Aspergillus Fumigatus Neutrophil Response
Fréalle, É., Gosset, P., Leroy, S., Delattre, C., Wacrenier, A., Zenzmaier, C., Zawadzki, C., Aliouat, E. M., & Perkhofer, S. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0190 · Cited by 8
Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL
Zhang, D., Harris, H. M., Kelly, A., ROBBINS, D. W., Tan, M., Ingallinera, T. G., Bence, N., Sands, A., Baskar, S., Herman, S. E. M., et al. (2019) · Blood · doi:10.1182/blood-2019-126921 · Cited by 3
Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1
Cited by
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211582 · Cited by 489
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Microglia in multiple sclerosis: protectors turn destroyers
Yong, V. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.023 · Cited by 185
Bruton’s tyrosine kinase inhibition in multiple sclerosis
Schneider, R., & Oh, J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01229-z · Cited by 47
Metadata
- Authors
- Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-11
- Volume
- 9
- Pages
- 630942-630942
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3139157067
- Cited by
- 267
- References
- 148
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.